drugset / Trial / NCT01925638

Effect of Ketoconazole on the Pharmacokinetics of Refametinib

NCT01925638

Phase 1 Completed 18 enrolled Bayer
NaSingle-groupOpen-label

Summary

The purpose of this study is to see if there is a difference between the way your body absorbs and distributes BAY86-9766 when given alone or in combination with ketoconazole, a drug which may affect how much BAY86-9766 is absorbed, distributed or eliminated from the body

Timeline

Start
2013-09
Primary completion
2013-12
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketoconazole Small molecule 400 mg
Subject Refametinib Small molecule 10 mg
Subject Refametinib Small molecule 20 mg
Subject Refametinib Small molecule 30 mg

Indications

No indication recorded.